News

Navigating Cognitive Health: Understanding the 12-Question Test for Dementia

The 2 Finger Test in Dementia

Understanding Alzheimer's Disease: A Comprehensive Guide

Advancing Alzheimer's Treatment Means Using The Best Biomarker(s) — But Which?

SYNAPS Dx Honors Caregivers, Patients and Families During National Alzheimer’s Disease Awareness Month and National Family Caregivers Month

Navigating Dementia Care: Unveiling the GUIDE Model, the Importance of Annual Wellness Visits and Advancements in Alzheimer’s Diagnosis

SYNAPS Dx Honors Residents, Families, Staff and Volunteers in Assisted Living Communities

Alzheimer’s Disease: Know the Factors, Recognize Opportunities to Reduce Risk

SYNAPS Dx President and CEO, Frank Amato, Featured on Business Ninjas Podcast

Leqembi, First Drug to Demonstrate Slowed Progression of Alzheimer’s Disease, Earns Full FDA Approval

SYNAPS Dx DISCERN™ Test Provides Accurate Diagnosis of Alzheimer’s Disease, Optimizes Prescribing, Minimizes Patient Risks and Informs Coverage Decisions for Leqembi™

Update: FDA Approves Rexulti to Treat Agitation Associated with Alzheimer’s Disease

New Recommendation from FDA Advisory Committee: Leqembi Expected to Earn Full FDA Approval to Slow Progression of Alzheimer’s Disease

June 21st is the “Longest Day”: Join Us in Raising Awareness of Alzheimer’s Disease

SYNAPS Dx President and CEO, Frank Amato, Featured in Surviving Your Brain podcast with Philippe Douyon, MD

Donanemab Clinical Trial Data Underscores Need for DISCERN™ Accurate Diagnostic Test for Alzheimer’s Disease, Highlights Physician Shortage in Rural Areas

June as Alzheimer’s & Brain Awareness Month Raises Importance of Early Diagnosis

Older Americans Month Concludes with Senior Health & Fitness Day

New Recommendation from FDA Advisory Committee: Using Rexulti to Treat Agitation Associated with Alzheimer’s Disease

Six Ways to Support Cognitive Health for Older Adults

The Cost Burdens of Diagnosing and Treating Alzheimer’s Disease: Alarming Issues for Patients, Providers and Payers Nationwide

Clinician Alert: Identify the Right Patients at the Right Time for Disease Modifying Therapies to Address Alzheimer’s Disease

Seven ways to care for your brain

FDA approves Alzheimer’s agent Leqembi shortly after release of congressional Aduhelm report